Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| beta-Lactamases | 5 | 2025 | 216 | 0.900 |
Why?
|
| Pseudomonas Phages | 2 | 2021 | 11 | 0.850 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2014 | 125 | 0.760 |
Why?
|
| Sewage | 2 | 2021 | 10 | 0.730 |
Why?
|
| Rivers | 2 | 2021 | 11 | 0.730 |
Why?
|
| Positron-Emission Tomography | 3 | 2014 | 294 | 0.710 |
Why?
|
| Anti-Bacterial Agents | 11 | 2026 | 2565 | 0.700 |
Why?
|
| Klebsiella Infections | 2 | 2018 | 59 | 0.670 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 4 | 2025 | 156 | 0.620 |
Why?
|
| Iran | 13 | 2026 | 97 | 0.620 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2018 | 2112 | 0.580 |
Why?
|
| Embolism | 1 | 2018 | 38 | 0.540 |
Why?
|
| Foreign-Body Migration | 1 | 2018 | 64 | 0.530 |
Why?
|
| Klebsiella pneumoniae | 1 | 2018 | 84 | 0.520 |
Why?
|
| Microbial Sensitivity Tests | 8 | 2026 | 846 | 0.500 |
Why?
|
| Wounds, Gunshot | 1 | 2018 | 146 | 0.500 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2025 | 396 | 0.490 |
Why?
|
| Intensive Care Units | 2 | 2024 | 522 | 0.470 |
Why?
|
| Escherichia coli | 5 | 2026 | 995 | 0.460 |
Why?
|
| Escherichia coli Infections | 3 | 2026 | 196 | 0.430 |
Why?
|
| Cardiac Catheterization | 1 | 2018 | 623 | 0.400 |
Why?
|
| Phage Therapy | 3 | 2024 | 52 | 0.400 |
Why?
|
| Microbiota | 3 | 2024 | 438 | 0.400 |
Why?
|
| Heart Ventricles | 1 | 2018 | 762 | 0.390 |
Why?
|
| Veins | 1 | 2013 | 96 | 0.390 |
Why?
|
| Whole Body Imaging | 1 | 2013 | 28 | 0.380 |
Why?
|
| Multimodal Imaging | 2 | 2014 | 111 | 0.380 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2025 | 230 | 0.360 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2025 | 177 | 0.350 |
Why?
|
| Colistin | 2 | 2022 | 30 | 0.340 |
Why?
|
| Helicobacter pylori | 4 | 2019 | 1367 | 0.330 |
Why?
|
| Pseudomonas Infections | 2 | 2021 | 117 | 0.310 |
Why?
|
| Endovascular Procedures | 1 | 2018 | 786 | 0.310 |
Why?
|
| Probiotics | 2 | 2023 | 226 | 0.290 |
Why?
|
| Staphylococcal Infections | 3 | 2024 | 563 | 0.280 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2025 | 37 | 0.280 |
Why?
|
| Bone Neoplasms | 1 | 2013 | 474 | 0.270 |
Why?
|
| Polymerase Chain Reaction | 3 | 2024 | 1457 | 0.270 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2007 | 64 | 0.260 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2024 | 832 | 0.250 |
Why?
|
| Lactobacillus | 1 | 2026 | 41 | 0.240 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 881 | 0.220 |
Why?
|
| Staphylococcal Protein A | 1 | 2024 | 7 | 0.220 |
Why?
|
| Integrons | 1 | 2024 | 1 | 0.210 |
Why?
|
| Organometallic Compounds | 2 | 2015 | 111 | 0.210 |
Why?
|
| Humans | 41 | 2026 | 130870 | 0.210 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2024 | 8 | 0.210 |
Why?
|
| Bacterial Proteins | 4 | 2024 | 940 | 0.210 |
Why?
|
| Surgical Wound | 1 | 2024 | 21 | 0.210 |
Why?
|
| Diarrhea | 1 | 2026 | 313 | 0.200 |
Why?
|
| Fibroblasts | 1 | 2007 | 860 | 0.200 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 3807 | 0.200 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2024 | 97 | 0.200 |
Why?
|
| Nanotubes, Carbon | 1 | 2023 | 15 | 0.190 |
Why?
|
| Escherichia coli Proteins | 1 | 2025 | 317 | 0.190 |
Why?
|
| Embolization, Therapeutic | 2 | 2019 | 231 | 0.190 |
Why?
|
| Adipose Tissue | 1 | 2025 | 495 | 0.190 |
Why?
|
| Complementary Therapies | 1 | 2023 | 45 | 0.190 |
Why?
|
| Metal Nanoparticles | 1 | 2023 | 55 | 0.180 |
Why?
|
| Antigens, Bacterial | 2 | 2019 | 315 | 0.180 |
Why?
|
| Biosensing Techniques | 1 | 2023 | 79 | 0.180 |
Why?
|
| Mouth | 1 | 2022 | 64 | 0.180 |
Why?
|
| Stomach Neoplasms | 1 | 2007 | 577 | 0.170 |
Why?
|
| Host Specificity | 1 | 2021 | 14 | 0.170 |
Why?
|
| Cross Infection | 1 | 2024 | 332 | 0.170 |
Why?
|
| Environmental Microbiology | 1 | 2021 | 16 | 0.170 |
Why?
|
| Urinary Tract Infections | 1 | 2025 | 329 | 0.170 |
Why?
|
| Apoptosis | 1 | 2007 | 1844 | 0.170 |
Why?
|
| Adult | 17 | 2025 | 31245 | 0.170 |
Why?
|
| Bacterial Infections | 1 | 2024 | 323 | 0.170 |
Why?
|
| Tonsillitis | 1 | 2020 | 13 | 0.160 |
Why?
|
| Palatine Tonsil | 1 | 2020 | 34 | 0.160 |
Why?
|
| Stem Cells | 1 | 2025 | 715 | 0.160 |
Why?
|
| Genome, Viral | 1 | 2021 | 161 | 0.160 |
Why?
|
| Helicobacter Infections | 3 | 2019 | 1307 | 0.160 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 989 | 0.160 |
Why?
|
| Mesentery | 1 | 2020 | 26 | 0.160 |
Why?
|
| Burns | 1 | 2021 | 91 | 0.160 |
Why?
|
| Mesenteric Veins | 1 | 2020 | 14 | 0.160 |
Why?
|
| Mesenteric Ischemia | 1 | 2020 | 30 | 0.160 |
Why?
|
| Middle Aged | 17 | 2025 | 28517 | 0.160 |
Why?
|
| Recombination, Genetic | 1 | 2021 | 422 | 0.150 |
Why?
|
| Radial Artery | 1 | 2019 | 33 | 0.150 |
Why?
|
| Acinetobacter Infections | 1 | 2020 | 33 | 0.150 |
Why?
|
| Male | 20 | 2025 | 64772 | 0.150 |
Why?
|
| Anti-Infective Agents | 1 | 2022 | 266 | 0.150 |
Why?
|
| Acinetobacter baumannii | 1 | 2020 | 45 | 0.150 |
Why?
|
| Oxazolidinones | 1 | 2019 | 32 | 0.150 |
Why?
|
| Leiomyoma | 1 | 2019 | 70 | 0.150 |
Why?
|
| Femoral Artery | 1 | 2019 | 135 | 0.150 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 216 | 0.150 |
Why?
|
| Tetrazoles | 1 | 2019 | 72 | 0.150 |
Why?
|
| Interleukin-17 | 1 | 2019 | 126 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2023 | 395 | 0.140 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 101 | 0.140 |
Why?
|
| Nalidixic Acid | 1 | 2018 | 3 | 0.140 |
Why?
|
| Clavulanic Acid | 1 | 2018 | 7 | 0.140 |
Why?
|
| Colitis | 1 | 2020 | 164 | 0.140 |
Why?
|
| Neoplasms | 1 | 2013 | 2957 | 0.140 |
Why?
|
| Imipenem | 1 | 2018 | 9 | 0.140 |
Why?
|
| Computed Tomography Angiography | 1 | 2020 | 215 | 0.140 |
Why?
|
| Adhesins, Bacterial | 1 | 2019 | 74 | 0.140 |
Why?
|
| Stomach Diseases | 1 | 2019 | 56 | 0.140 |
Why?
|
| Staphylococcus aureus | 2 | 2020 | 482 | 0.140 |
Why?
|
| Venous Cutdown | 1 | 2018 | 2 | 0.140 |
Why?
|
| Klebsiella | 1 | 2018 | 11 | 0.140 |
Why?
|
| Catheterization, Peripheral | 1 | 2019 | 126 | 0.140 |
Why?
|
| Molecular Epidemiology | 1 | 2018 | 145 | 0.130 |
Why?
|
| Femoral Vein | 1 | 2018 | 48 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 1 | 2019 | 391 | 0.130 |
Why?
|
| Aged | 10 | 2024 | 20974 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 235 | 0.130 |
Why?
|
| beta-Lactamase Inhibitors | 1 | 2018 | 61 | 0.130 |
Why?
|
| Amoxicillin | 1 | 2018 | 117 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 249 | 0.130 |
Why?
|
| Contrast Media | 1 | 2020 | 491 | 0.120 |
Why?
|
| Germanium | 1 | 2015 | 1 | 0.120 |
Why?
|
| Radiochemistry | 1 | 2015 | 3 | 0.120 |
Why?
|
| Radioisotopes | 1 | 2015 | 26 | 0.120 |
Why?
|
| Plasmids | 1 | 2016 | 451 | 0.110 |
Why?
|
| Female | 20 | 2025 | 70560 | 0.110 |
Why?
|
| DNA, Bacterial | 2 | 2020 | 484 | 0.110 |
Why?
|
| Bacteria | 3 | 2024 | 521 | 0.110 |
Why?
|
| Radiation Dosage | 1 | 2015 | 137 | 0.110 |
Why?
|
| Epidermal Growth Factor | 2 | 2005 | 116 | 0.110 |
Why?
|
| Mental Disorders | 1 | 2023 | 896 | 0.110 |
Why?
|
| Pandemics | 1 | 2022 | 1158 | 0.110 |
Why?
|
| Octreotide | 1 | 2014 | 24 | 0.110 |
Why?
|
| Genetic Variation | 1 | 2021 | 1555 | 0.110 |
Why?
|
| Digestive System Neoplasms | 1 | 2014 | 12 | 0.110 |
Why?
|
| Saliva | 2 | 2005 | 125 | 0.110 |
Why?
|
| Receptors, Somatostatin | 1 | 2014 | 55 | 0.100 |
Why?
|
| Phlebography | 1 | 2013 | 43 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 164 | 0.100 |
Why?
|
| Prevalence | 4 | 2024 | 2694 | 0.100 |
Why?
|
| Neuroendocrine Tumors | 1 | 2014 | 69 | 0.100 |
Why?
|
| Diagnosis, Differential | 3 | 2013 | 1892 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 6801 | 0.090 |
Why?
|
| Nitric Oxide | 2 | 2005 | 466 | 0.090 |
Why?
|
| Nasal Polyps | 1 | 2011 | 28 | 0.090 |
Why?
|
| Urease | 1 | 2011 | 73 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2020 | 12914 | 0.080 |
Why?
|
| Nasal Mucosa | 1 | 2011 | 90 | 0.080 |
Why?
|
| Interferon-gamma | 2 | 2025 | 548 | 0.080 |
Why?
|
| Oxidative Stress | 2 | 2005 | 797 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2013 | 1501 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 342 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 1311 | 0.080 |
Why?
|
| Adolescent | 5 | 2020 | 20820 | 0.070 |
Why?
|
| Cystic Duct | 1 | 2008 | 1 | 0.070 |
Why?
|
| Phylogeny | 2 | 2021 | 693 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 3827 | 0.070 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2008 | 39 | 0.070 |
Why?
|
| Case-Control Studies | 4 | 2022 | 3393 | 0.070 |
Why?
|
| Densitometry | 1 | 2007 | 16 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2007 | 293 | 0.060 |
Why?
|
| Species Specificity | 1 | 2007 | 482 | 0.060 |
Why?
|
| Thyroid Diseases | 1 | 2007 | 28 | 0.060 |
Why?
|
| Olfaction Disorders | 1 | 2006 | 24 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2006 | 95 | 0.060 |
Why?
|
| Genes, Recessive | 1 | 2007 | 199 | 0.060 |
Why?
|
| Urinary Calculi | 1 | 2006 | 16 | 0.060 |
Why?
|
| Cathelicidins | 1 | 2025 | 13 | 0.060 |
Why?
|
| Calcium Phosphates | 1 | 2006 | 18 | 0.060 |
Why?
|
| Proteus mirabilis | 1 | 2025 | 13 | 0.060 |
Why?
|
| Calcium Oxalate | 1 | 2006 | 24 | 0.060 |
Why?
|
| Melanoma | 1 | 2013 | 925 | 0.060 |
Why?
|
| Risk | 1 | 2007 | 729 | 0.060 |
Why?
|
| Culture Media, Conditioned | 1 | 2025 | 84 | 0.060 |
Why?
|
| Pentoxifylline | 1 | 2005 | 20 | 0.060 |
Why?
|
| Proteinuria | 1 | 2006 | 108 | 0.060 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2007 | 156 | 0.060 |
Why?
|
| Craniocerebral Trauma | 1 | 2006 | 142 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2025 | 2907 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2005 | 1448 | 0.050 |
Why?
|
| Mutation | 3 | 2023 | 6140 | 0.050 |
Why?
|
| Allopurinol | 1 | 2004 | 79 | 0.050 |
Why?
|
| Genes, Bacterial | 1 | 2024 | 216 | 0.050 |
Why?
|
| Young Adult | 4 | 2020 | 10042 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 1548 | 0.050 |
Why?
|
| Electrochemical Techniques | 1 | 2023 | 8 | 0.050 |
Why?
|
| Antioxidants | 1 | 2005 | 335 | 0.050 |
Why?
|
| Gold | 1 | 2023 | 55 | 0.050 |
Why?
|
| Bone Density | 1 | 2005 | 369 | 0.050 |
Why?
|
| Aggregatibacter actinomycetemcomitans | 1 | 2022 | 5 | 0.050 |
Why?
|
| Laboratories | 1 | 2023 | 79 | 0.050 |
Why?
|
| Feces | 1 | 2026 | 722 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 78 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2018 | 15018 | 0.050 |
Why?
|
| Biopsy | 2 | 2019 | 1244 | 0.040 |
Why?
|
| Acetaminophen | 1 | 2023 | 99 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 2024 | 265 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2021 | 111 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2023 | 316 | 0.040 |
Why?
|
| Child | 2 | 2018 | 26218 | 0.040 |
Why?
|
| Colony Count, Microbial | 1 | 2020 | 85 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2020 | 48 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 3-gamma | 1 | 2019 | 4 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 3727 | 0.040 |
Why?
|
| Time Factors | 3 | 2019 | 6217 | 0.040 |
Why?
|
| Haplotypes | 1 | 2021 | 522 | 0.040 |
Why?
|
| Punctures | 1 | 2019 | 58 | 0.040 |
Why?
|
| Carbapenems | 1 | 2020 | 45 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 2020 | 86 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 2019 | 145 | 0.040 |
Why?
|
| Coinfection | 1 | 2021 | 188 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2019 | 74 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 502 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2019 | 237 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2019 | 184 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2019 | 158 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2019 | 96 | 0.040 |
Why?
|
| Interleukins | 1 | 2019 | 122 | 0.040 |
Why?
|
| Body Height | 1 | 2019 | 196 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2019 | 201 | 0.040 |
Why?
|
| Superantigens | 1 | 2018 | 20 | 0.040 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2018 | 22 | 0.040 |
Why?
|
| Enterotoxins | 1 | 2018 | 75 | 0.040 |
Why?
|
| Virulence | 1 | 2019 | 271 | 0.030 |
Why?
|
| Genotype | 2 | 2019 | 2606 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 653 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 975 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2021 | 678 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2022 | 1457 | 0.030 |
Why?
|
| Bacterial Toxins | 1 | 2018 | 170 | 0.030 |
Why?
|
| Colon | 1 | 2020 | 361 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2020 | 17673 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 887 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 790 | 0.030 |
Why?
|
| Stomach | 1 | 2019 | 272 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2008 | 3131 | 0.030 |
Why?
|
| Cytokines | 1 | 2022 | 1336 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 1324 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 2925 | 0.030 |
Why?
|
| Animals | 3 | 2024 | 33982 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1238 | 0.030 |
Why?
|
| Ion Exchange | 1 | 2015 | 4 | 0.030 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2015 | 8 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 2 | 2005 | 20 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 295 | 0.030 |
Why?
|
| Lipid Peroxidation | 2 | 2005 | 92 | 0.030 |
Why?
|
| Vaccines | 1 | 2019 | 383 | 0.030 |
Why?
|
| Brain | 1 | 2006 | 3201 | 0.030 |
Why?
|
| Bacteremia | 1 | 2018 | 428 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 277 | 0.020 |
Why?
|
| Mice | 2 | 2020 | 18268 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 1082 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2005 | 1639 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 5199 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4683 | 0.020 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2008 | 11 | 0.020 |
Why?
|
| Cholangiography | 1 | 2008 | 13 | 0.020 |
Why?
|
| Cholelithiasis | 1 | 2008 | 16 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2303 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 2212 | 0.020 |
Why?
|
| Vestibule, Labyrinth | 1 | 2007 | 21 | 0.020 |
Why?
|
| Thyroxine | 1 | 2007 | 59 | 0.020 |
Why?
|
| Sulfonylurea Compounds | 1 | 2005 | 21 | 0.010 |
Why?
|
| Texas | 1 | 2014 | 3635 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 2005 | 54 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 10978 | 0.010 |
Why?
|
| Femur | 1 | 2005 | 79 | 0.010 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2005 | 61 | 0.010 |
Why?
|
| Postmenopause | 1 | 2005 | 136 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 576 | 0.010 |
Why?
|
| Osteoporosis | 1 | 2005 | 133 | 0.010 |
Why?
|
| Quality of Life | 1 | 2014 | 2082 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 680 | 0.010 |
Why?
|
| Syndrome | 1 | 2007 | 1162 | 0.010 |
Why?
|
| Incidence | 1 | 2011 | 3336 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 563 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2005 | 325 | 0.010 |
Why?
|
| Metformin | 1 | 2005 | 171 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2005 | 483 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2005 | 1681 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 3040 | 0.010 |
Why?
|
| Prognosis | 1 | 2005 | 4913 | 0.010 |
Why?
|